Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension.
Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension.
复制标题
DOI：
10.1097/hjh.0b013e328332bcdb
复制
发表时间：
2010-02
影响因子：
4.9
通讯作者：
Sun Z
中科院分区：
文献类型：
--
作者：
Crosswhite P;Sun Z
肺动脉高压（PAH）是一种慢性进行性疾病，其特征是肺动脉压持续升高，伴有右心室肥大（RVH）。目前肺动脉高压的治疗是有限的，并且由于疾病的病因和发病机制未知而仅提供症状缓解。肺动脉的血管收缩和结构重塑（VSMC增殖增强）均有助于PAH的进展过程，而与不同的基础原因无关。然而，PAH的确切分子机制尚未完全了解。本文综述了近年来多环芳烃的发病机制研究进展。具体而言，这篇综述主要集中在一氧化氮（NO），氧化应激和炎症以及这些因素如何有助于PAH的发展和进展。该综述还讨论了治疗肺动脉高压的最新和潜在的治疗进展。
Pulmonary arterial hypertension (PAH) is a chronic and progressive disease characterized by a persistent elevation of pulmonary artery pressure accompanied by right ventricular hypertrophy (RVH). The current treatment for pulmonary hypertension is limited and only provides symptomatic relief due to unknown etiology and pathogenesis of the disease. Both vasoconstriction and structural remodeling (enhanced proliferation of VSMC) of the pulmonary arteries contribute to the progressive course of PAH, irrespective of different underlying causes. The exact molecular mechanism of PAH, however, is not fully understood. The purpose of this review is to provide recent advances in the mechanistic investigation of PAH. Specifically, this review focuses on nitric oxide (NO), oxidative stress and inflammation and how these factors contribute to the development and progression of PAH. This review also discusses recent and potential therapeutic advancements for the treatment of PAH.